Skip to search formSkip to main contentSkip to account menu

Thrombopoietin Receptor Agonists [MoA]

Known as: Thrombopoietin Receptor Agonists 
National Institutes of Health

Related topics

Related topics

3 relations
eltrombopageltrombopag 25 MG Oral Tabletromiplostim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
2018
2018
Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy
BackgroundImmune thrombocytopenic purpura (ITP) is primarily characterized by immune-mediated destruction of platelets in… 
Review
2017
Review
2017
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists
Since its discovery, the thrombopoietin (TPO) pathway has been an important pharmaceutical target for the treatment of… 
2016
2016
Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand
Background: Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the… 
Review
2015
Review
2015
Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go… 
2015
2015
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
Background: The aim of this study was to evaluate the treatment reality for outpatients with immune thrombocytopenia (ITP… 
Highly Cited
2013
Highly Cited
2013
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However, continuous therapy… 
Review
2013
Review
2013
Bone Marrow Fibrosis In Immune Thrombocytopenia (ITP) Patients Treated With Thrombopoietin Receptor Agonists (TRA) – a Single Center Long-Term Follow-Up
![Graphic][1] Introduction TRAs increase platelet counts by stimulating the TPO-receptor. A known effect of TRA treatment is… 
2013
2013
Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities
Thrombopoietin receptor agonists (TRAs) offer new opportunities for the treatment of chronic immune thrombocytopenia (ITP… 
2011
2011
Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists
Aim: Thrombopoietin receptor agonists (Tpo increase platelet counts in the majority of chronic autoimmune thrombocytopenia… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)